Evidence map›Paper›PMID 42717648›Full record

ArticleArchiv der Pharmazie2026

New Chromene Derivatives as Promising VEGFR-2 Inhibitors: Experimental Cytotoxicity and Comprehensive Computational Characterization.

Hazem Elkady, Aisha A Alsfouk, Eslam B Elkaeed, Walid E Elgammal, Hazem A Mahdy, Ahmed Nofal, Ibrahim H Eissa, Dalal Z Husein, Fatma G Amin, Ahmed M Metwaly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hazem ElkadyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-0893-6703
Aisha A AlsfoukDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0003-4497-5013
Eslam B ElkaeedDepartment of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Diriyah, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-2546-8035
Walid E ElgammalDepartment of Chemistry, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt.ORCID https://orcid.org/0000-0002-5982-5635
Hazem A MahdyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-6620-241X
Ahmed NofalFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0009-0001-1820-9684
Ibrahim H EissaPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-6955-2263
Dalal Z HuseinChemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.ORCID https://orcid.org/0000-0001-7552-0914
Fatma G AminPhysics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Ahmed M MetwalyPharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.ORCID https://orcid.org/0000-0001-8566-1980

Funding

Princess Nourah bint Abdulrahman University PNURSP2026R116
6 · The paper itself

Abstract

A new series of chromene derivatives (12-19) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF-7, MDA-MB-231, HepG-2, and HCT-116) alongside normal human cells (WI-38 and WISH), in addition to a VEGFR-2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC

Indexed as

Antineoplastic AgentsBenzopyransProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2ApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug DesignDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBenzopyransKDR protein, humanProtein Kinase InhibitorsTyrosine Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2anti‐cancerapoptosischromenesin silicoin vitroVEGFR‐2

Identifiers

PMID42717648
PMCPMC13559204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.